Latest news with #EdDeng
The Sun
6 days ago
- Health
- The Sun
Health2Sync and Novo Nordisk Pharma Korea, Ltd. Launch Smart Cap Mallya® for FlexTouch® Insulin Pens Integration in South Korea, Enhancing insulin administration via Digital Diabetes Care
SEOUL, SOUTH KOREA - Media OutReach Newswire - 9 July 2025 - Health2Sync, Asia's leading digital chronic disease management platform, announced the successful integration of Smart Cap Mallya® for FlexTouch® Insulin Pens data into SugarGenie, its Korean-market diabetes management app. Mallya® enables automatic recording of insulin injection details. This data can be synced directly into a patient's digital health record and shared with healthcare providers via SugarGenie, HealthSync's solution in Korea. This innovation comes at a critical moment. Managing insulin administration records is a challenging task for both diabetes patients and healthcare professionals. In fact, a multinational survey of diabetes patients receiving insulin treatment and physicians treating diabetes patients found that 27.6% of patients experience difficulty administering insulin at the prescribed time or with meals. In the same study, 54.5% of physicians reported that their patients experience difficulty administering insulin at the prescribed time or with meals. Mallya®, when paired with Health2Sync's connected ecosystem, significantly lowers this burden. Patients using FlexTouch® insulin pens can now have their dosage, time, and frequency data recorded and visualized in real time within the SugarGenie app. 'This integration is connecting yet another integral part in digital diabetes care,' said Ed Deng, CEO and Co-founder of Health2Sync. 'By connecting the data of Mallya® to SugarGenie, we're improving accuracy in insulin tracking and expanding the depth of data available to patients and care teams. Our platform enables insulin logs to be viewed alongside blood glucose, meals, and physical activity, offering a full circle understanding of each patient's health context.' Deng continued: 'For healthcare professionals, this means faster, smarter decisions. Our care provider portal lets clinicians view real-time patient data We're turning disconnected data points into a unified, actionable picture of care, without placing additional burden on patients.' SugarGenie's integration with Mallya® supports remote care models and automated record-keeping—an increasingly critical combination for long-term chronic condition management in South Korea. With its clean interface, real-time sync, and care team dashboard, SugarGenie is a key digital infrastructure in Korea's diabetes treatment landscape. 'Digital healthcare has become a key tool in enhancing the efficiency and convenience of diabetes treatment,' said Kasper Roseeuw Poulsen, General Manager of Novo Nordisk Pharma Korea, Ltd.. 'For over a century, Novo Nordisk has supported patients through holistic solutions, and our collaboration with Health2Sync is also a continuation of that commitment. We hope this strategic collaboration will help create a more systematic and efficient treatment environment for both patients and healthcare professionals in Korea.'
Zawya
09-07-2025
- Health
- Zawya
Health2Sync and Novo Nordisk Pharma Korea, Ltd. Launch Smart Cap Mallya® for FlexTouch® Insulin Pens Integration in South Korea, Enhancing insulin administration via Digital Diabetes Care
SEOUL, SOUTH KOREA - Media OutReach Newswire - 9 July 2025 - Health2Sync, Asia's leading digital chronic disease management platform, announced the successful integration of Smart Cap Mallya® for FlexTouch® Insulin Pens data into SugarGenie, its Korean-market diabetes management app. Mallya® enables automatic recording of insulin injection details. This data can be synced directly into a patient's digital health record and shared with healthcare providers via SugarGenie, HealthSync's solution in Korea. This innovation comes at a critical moment. Managing insulin administration records is a challenging task for both diabetes patients and healthcare professionals. In fact, a multinational survey of diabetes patients receiving insulin treatment and physicians treating diabetes patients found that 27.6% of patients experience difficulty administering insulin at the prescribed time or with meals. In the same study, 54.5% of physicians reported that their patients experience difficulty administering insulin at the prescribed time or with meals. Mallya®, when paired with Health2Sync's connected ecosystem, significantly lowers this burden. Patients using FlexTouch® insulin pens can now have their dosage, time, and frequency data recorded and visualized in real time within the SugarGenie app. "This integration is connecting yet another integral part in digital diabetes care," said Ed Deng, CEO and Co-founder of Health2Sync. "By connecting the data of Mallya® to SugarGenie, we're improving accuracy in insulin tracking and expanding the depth of data available to patients and care teams. Our platform enables insulin logs to be viewed alongside blood glucose, meals, and physical activity, offering a full circle understanding of each patient's health context." Deng continued: "For healthcare professionals, this means faster, smarter decisions. Our care provider portal lets clinicians view real-time patient data We're turning disconnected data points into a unified, actionable picture of care, without placing additional burden on patients." SugarGenie's integration with Mallya® supports remote care models and automated record-keeping—an increasingly critical combination for long-term chronic condition management in South Korea. With its clean interface, real-time sync, and care team dashboard, SugarGenie is a key digital infrastructure in Korea's diabetes treatment landscape. "Digital healthcare has become a key tool in enhancing the efficiency and convenience of diabetes treatment," said Kasper Roseeuw Poulsen, General Manager of Novo Nordisk Pharma Korea, Ltd.. "For over a century, Novo Nordisk has supported patients through holistic solutions, and our collaboration with Health2Sync is also a continuation of that commitment. We hope this strategic collaboration will help create a more systematic and efficient treatment environment for both patients and healthcare professionals in Korea." Hashtag: #health2sync #diabetesmanagement #digitaltherapeutis #digitalhealth The issuer is solely responsible for the content of this announcement. Health2Sync Founded in 2013, Health2Sync is a leading digital health company in Asia focused on delivering personalized and comprehensive solutions for chronic disease management. Its core offerings include a mobile patient app and a cloud-based analytics platform for healthcare providers, designed to drive measurable improvements in blood glucose outcomes. With the most extensive clinical network in Asia, Health2Sync offers a scalable, data-driven approach to diabetes care. The platform empowers patients with tailored insights, enabling healthcare professionals and caregivers to support them remotely and fostering continuous, collaborative care throughout the entire treatment journey. For more information, please visit About SugarGenie App Health2Sync's SugarGenie app collects biometric information measured by medical devices and transmits it to a platform via encrypted protocols, allowing patient data to be shared with family, caregivers, and healthcare institutions.5 It integrates data such as blood glucose level, blood pressure, weight, and user-inputted dietary and exercise information. It transforms it into visual reports to provide personalized feedback, enable effective communication between patients and healthcare professionals, and monitor real-time health status. As of June 2025, Health2Sync has over 1.5 million users worldwide. Health2Sync
Zawya
05-03-2025
- Business
- Zawya
Health2Sync Completes an Oversubscribed Round of US$20 Million to Fuel Market Expansion and Prepares for Public Listing
Health2Sync, Asia's leading chronic disease management platform, has secured over $20 million in a Series C funding round, paving the way for a planned public listing on the Taiwan capital markets. This capital will fuel strategic growth as Health2Sync prepares for its IPO: expanding into new markets (Japan, South Korea, Australia), developing new disease management programs (weight loss, hypertension, GLP-1), and deepening AI integration. This investment reflects strong investor confidence in Health2Sync's established market leadership, its vision to transform chronic disease management through data-driven solutions, and its strategic path towards a public listing. TAIPEI, TAIWAN - Media OutReach Newswire - 5 March 2025 - Health2Sync (H2), a leading digital health company specializing in chronic disease management, today announced it has raised over US$20 million in a Series C funding round and earlier extension round. This investment will propel the company's growth initiatives, including expansion into new markets, development of innovative programs, and preparations for a public listing in Taiwan. The funding round was led by Taiwania Capital, with participation from prominent investors, including Wistron, Pegatron, BE Health Ventures, ABIES Capital, and Cathay Venture. The strong support from new and existing investors underscores confidence in Health2Sync's vision and track record of what it has developed as Asia's largest chronic disease management solution. "We are thrilled to welcome our new groups of investors to join our vision of transformative data-driven disease management," said Ed Deng, Co-founder and CEO of Health2Sync. "In this mission, we constantly face challenges on all fronts, this funding validates our traction to date and enables us to capture opportunities, enhance our product offerings, and ultimately improve the lives of millions of people living with diabetes and related conditions." "Digital disease management solutions have always been one of the key areas of our investment focus," said Michael Huang, Managing Partner of Taiwania Capital. "We are excited to see other investors supporting the Health2Sync team at a time when public healthcare systems across the globe are incorporating digital solutions as an integral part of managing chronic diseases such as diabetes." The Company has strategically deployed the newly acquired capital to support several key initiatives: Develop and launch a series of disease management programs: continue developing its innovative and personalized patient engagement programs to include a digital weight-loss program targeting the need for practical weight management tools, hypertension, and other sub-health symptoms, and adding digital GLP-1 engagement to the offering as payers in the region seek to enable further drug accessibility. Expansion in key markets: accelerate its growth in strategic geographies, including Japan, South Korea and Australia, especially capitalizing on the increasing demand from the public sector for digital health solutions. Introduce Insultrate, a Software-as-a-Medical Device (SaMD) for insulin self-titration, to other geographies. Deepen the use of AI: enhance the efficiency of disease management for patients and healthcare providers and elevate user experience to the next level. This funding round marks a significant milestone for Health2Sync as it prepares for a listing on the Taiwan capital markets. Hashtag: #health2sync #diabetesmanagement #digitaltherapeutis #digitalhealth #startup The issuer is solely responsible for the content of this announcement. Health2Sync Founded in 2013, Health2Sync offers digital solutions to help people manage their health with chronic diseases, pre-diabetes, or weight concerns. The company's achievements include being the first approved digital therapeutics in Taiwan for its insulin dosage titration software, Insultrate, which it co-developed with Sanofi. The company has also received the title of "NEXT BIG" Startup from the Taiwan National Development Council of Taiwan and has served over 1.4 million users worldwide. For more information, please visit Health2Sync
